Stable size distribution of amyloid plaques over the course of alzheimer disease

Journal of Neuropathology and Experimental Neurology

Volumn 71, Issue 8, 2012, Pages 694-701

  Serrano Pozo, Alberto ^a   Mielke, Matthew L ^a   Muzitansky, Alona ^a   Gómez Isla, Teresa ^a   Growdon, John H ^a   Bacskai, Brian J ^a   Betensky, Rebecca A ^a,b   Frosch, Matthew P ^a   Hyman, Bradley T ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Alzheimer disease; Amyloid plaques; APOE genotype; Dense core plaques; Plaque growth; Plaque size

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E4;

AGED; ALLELE; ALZHEIMER DISEASE; AMYLOID PLAQUE; ARTICLE; AUTOPSY; CONTROLLED STUDY; COURSE EVALUATION; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; FEMALE; GENOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NEOCORTEX; ONSET AGE; PREDICTIVE VALUE; PRIORITY JOURNAL;

AGE OF ONSET; AGED; AGING; ALZHEIMER DISEASE; APOLIPOPROTEINS E; BRAIN; FEMALE; GENOTYPE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; PLAQUE, AMYLOID; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS;

EID: 84864447080     PISSN: 00223069     EISSN: 15546578     Source Type: Journal    
DOI: 10.1097/NEN.0b013e31825e77de     Document Type: Article

References (62)

1. Jarrett JT, Lansbury Jr PT. Seeding "one-dimensional crystallization" of amyloid: A pathogenic mechanism in Alzheimer's disease and scrapie? Cell 1993;73:1055-58
2. Barrow CJ, Zagosrki MG. Solution structures of A peptide and its constituent fragments: Relation to amyloid deposition. Science 1991;253: 179-82
3. Lomakin A, Chung DS, Benedek GB, et al. On the nucleation and growth of amyloid A-protein fibrils: Detection of nuclei and quantitation of rate constants. Proc Natl Acad Sci USA 1996;93:1125-29
4. Walsh DM, Lomakin A, Benedek GB, et al. Amyloid A-protein fibrillogenesis: Detection of a protofibrillar intermediate. J Biol Chem 1997;272: 22364-72
5. Walsh DM, Hartley DM, Kusumoto Y, et al. Amyloid A-protein fibrillogenesis: Structure and biological activity of protofibrillar intermediates. J Biol Chem 1999;274:25945-52
6. O'Nuallain B, Freir DB, Nicoll AJ, et al. Amyloid-A-protein dimers rapidly form stable synaptotoxic protofibrils. J Neurosci 2010;30: 14411-19
7. Meyer-Luehmann M, Coomaraswamy J, Bolmont T, et al. Exogenous induction of cerebral A-amyloidosis is governed by agent and host. Science 2006;313:1781-84
8. Christie RH, Bacskai BJ, Zipfel WR, et al. Growth arrest of individual senile plaques in a model of Alzheimer's disease observed by in vivo multiphoton microscopy. J Neurosci 2001;21:858-64
9. Meyer-Luehmann M, Spires-Jones TL, Prada C, et al. Rapid appearance and local toxicity of amyloid-A plaques in a mouse model of Alzheimer's disease. Nature 2008;451:720-24
10. Bolmont T, Haiss F, Eicke D, et al. Dynamics of the microglial/amyloid interaction indicate a role in plaque maintenance. J Neurosci 2008;28: 4283-92
11. Yan P, Bero AW, Cirrito JR, et al. Characterizing the appearance and growth of amyloid plaques in APP/PS1 mice. J Neurosci 2009;29: 10706-14
12. Burgold S, Bittner T, Dorostkar MM, et al. In vivo multiphoton imaging reveals gradual growth of newborn amyloid plaques over weeks. Acta Neuropathol 2011;121:327-35
13. Hefendehl JK, Wegenast-Braun BM, Liebig C, et al. Long-term in vivo imaging of A-amyloid plaque appearance and growth in a mouse model of cerebral A-amyloidosis. J Neurosci 2011;31:624-29
14. Mann DMA, Marcynuik B, Yates PO, et al. The progression of the pathological changes of Alzheimer's disease in frontal and temporal neocortex examined both at biopsy and at autopsy. Neuropathol Appl Neurobiol 1988;14:177-95
15. Arriagada PV, Growdon JH, Hedley-Whyte ET, et al. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 1992;42:631-39
16. Delaere P, He Y, Fayet G, et al. AA4 deposits are constant in the brain of the oldest old: An immunohistochemical study of 20 French centenarians. Neurobiol Aging 1993;14:191-94
17. Hyman BT, Marzloff K, Arriagada PV. The lack of accumulation of senile plaques or amyloid burden in Alzheimer's disease suggests a dynamic balance between amyloid deposition and resolution. J Neuropathol Exp Neurol 1993;52:594-600
18. Ingelsson M, Fukumoto H, Newell KL, et al. Early AA accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology 2004;62:925-31
19. Serrano-Pozo A, Mielke ML, Gomez-Isla T, et al. Reactive glia not only associates with plaques but also parallels tangles in Alzheimer disease. Am J Pathol 2011;179:1373-84
20. Engler H, Forsberg A, Almkvist O, et al. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain 2006;129:2856-66
21. Scheinin NM, Aalto S, Koikkalainen J, et al. Follow-up of 11CPIB uptake and brain volume in patients with Alzheimer disease and controls. Neurology 2009;73:1186-92
22. Koivunen J, Scheinin N, Virta JR, et al. Amyloid PET imaging in patients with mild cognitive impairment: A 2-year follow-up study. Neurology 2011;76:1085-90
23. Kadir A, Almkvist O, Forsberg A, et al. Dynamic changes in PET amyloid and FDG imaging at different stages of Alzheimer's disease. Neurobiol Aging 2012;33:198.e1-14
24. Villemagne VL, Pike KE, Chetelat G, et al. Longitudinal assessment of AA and cognition in aging and Alzheimer disease. Ann Neurol 2011;69: 181-92
25. Jack CR Jr, Lowe VJ, Weigand SD, et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: Implications for sequence of pathological events in Alzheimer's disease. Brain 2009;132: 1355-65
26. Rinne JO, Brooks DJ, Rossor MN, et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: A phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 2010;9:363-72
27. Ostrowitzki S, Deptula D, Thurfjell L, et al. Mechanisms of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol 2012;69:198-207
28. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-44
29. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute of Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Neurobiol Aging 1997;18:S1YS2
30. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med 2004;256:183-94
31. Morris JC. The Clinical Dementia Rating (CDR): Current version and scoring rules. Neurology 1993;43:2412-14
32. Braak H, Braak E. Neuropathological stageing of alzheimer-related changes. Acta Neuropathol 1991;82:239-59
33. Arriagada PV, Marzloff K, Hyman BT. Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern on Alzheimer's disease. Neurology 1992;42:1681-88
34. Ingelsson M, Shin Y, Irizarry MC, et al. Genotyping of apolipoprotein E: Comparative evaluation of different protocols. Curr Protoc Hum Genet 2003;14:1-13
35. Datta S, Satten GA. Rank-sum tests for clustered data. J Am Stat Assoc 2005;100:908-15
36. Heyman A, Peterson B, Fillenbaum G, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part XIV: Demographic and clinical predictors of survival in patients with Alzheimer's disease. Neurology 1996;46:656-60
37. Brookmeyer R, Corrada MM, Curriero FC, et al. Survival following a diagnosis of Alzheimer disease. Arch Neurol 2002;59:1764-67
38. Ganguli M, Dodge HH, Shen C, et al. Alzheimer disease and mortality: A 15-year epidemiological study. Arch Neurol 2005;62:779-84
39. Waring SC, Doody RS, Pavlik VN, et al. Survival among patients with dementia from a large multi-ethnic population. Alzheimer Dis Assoc Disord 2005;19:178-83
40. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993;261:921-23
41. Schmechel DE, Saunders AM, Strittmatter WJ, et al. Increased amyloid-A peptide deposition in cerebral cortex as a consequence of apolipopoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci USA 1993;90:9649-53
42. Hyman BT, West HL, Rebeck GW, et al. Quantitative analysis of senile plaques in Alzheimer disease: Observation of log-normal size distribution and molecular epidemiology of differences associated with apolipoprotein E genotype and trisomy 21 (Down syndrome). Proc Natl Acad Sci USA 1995;92:3586-90
43. Gomez-Isla T, West HL, Rebeck GW, et al. Clinical and pathological correlates of apolipoprotein E ?4 in Alzheimer's disease. Ann Neurol 1996;39:62-70
44. McNamara MJ, Gomez-Isla T, Hyman BT. Apolipoprotein E genotype and deposits of AA40 and AA42 in Alzheimer disease. Arch Neurol 1998; 55:1001-4
45. Maggio JE, Stimson ER, Ghilardi JR, et al. Reversible in vitro growth of Alzheimer disease A-amyloid plaques by deposition of labeled amyloid peptide. Proc Natl Acad Sci USA 1992;89:5462-66
46. Carulla N, Caddy GL, Hall DR, et al. Molecular recycling within amyloid fibrils. Nature 2005;436:554-58
47. Martins IC, Kuperstein I, Wilkisnson H, et al. Lipids revert inert AA amyloid fibrils to neurotoxic protofibrils that affect learning in mice. EMBO J 2008;27:224-33
48. Cruz L, Urbanc B, Buldyrev SV, et al. Aggregation and disaggregation of senile plaques in Alzheimer disease. Proc Natl Acad Sci USA 1997;94: 7612-16
49. Urbanc B, Cruz L, Buldyrev SV, et al. Dynamics of plaque formation in Alzheimer's disease. Biophys J 1999;76:1330-34
50. Oide T, Kinoshita T, Arima K. Regression stage senile plaques in the natural course of Alzheimer's disease. Neuropathol Appl Neurobiol 2006;32:539-56
51. Shankar GM, Li S, Mehta TH, et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 2008;14:837-42
52. Koffie RM, Meyer-Luehmann M, Hashimoto T, et al. Oligomeric amyloid-beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc Natl Acad Sci USA 2009;106:4012-17
53. Hong S, Quintero-Monzon O, Ostaszewski BL, et al. Dynamic analysis of amyloid A-protein in behaving mice reveals opposing changes in ISF versus parenchymal AA during age-related plaque formation. J Neurosci 2011;31:15861-69
54. Nielsen HM, Mulder SD, Belien JAM, et al. Astrocytic AA1-42 uptake is determined by AA-aggregation state and the presence of amyloidassociated proteins. Glia 2010;58:1235-46
55. Liu Z, Condello C, Schain A, et al. CX3CR1 in microglia regulates brain amyloid deposition through selective protofibrillar amyloid-A phagocytosis. J Neurosci 2010;30:17091-101
56. Mann DMA, Yates PO, Marcyniuk B. Some morphometric observations on the cerebral cortex and hippocampus in presenile Alzheimer's disease, senile dementia of Alzheimer type and Down's syndrome in middle age. J Neurol Sci 1985;69:139-59
57. Lippa CF, Saunders AM, Smith TW, et al. Familial and sporadic Alzheimer's disease: Neuropathology cannot exclude a final common pathway. Neurology 1996;46:406-12
58. Ho GJ, Hansen LA, Alford MF, et al. Age at onset is associated with disease severity in Lewy body variant and Alzheimer's disease. Neuroreport 2002;13:1825-28
59. Crook R, Verkkoniemi A, Perez-Tur J, et al. A variant of Alzheimer's disease with spastic paraparesis and unusual plaques due to deletion of exon 9 of presenilin 1. Nat Med 1998;4:452-55
60. Thal DR, Rub U, Orantes M, et al. Phases of AA-deposition in the human brain and its relevance for the development of AD. Neurology 2002;58: 1791-1800
61. Serrano-Pozo A, William CM, Ferrer I, et al. Beneficial effect of human antiYamyloid-A active immunization on neurite morphology and tau pathology. Brain 2010;133:1312-27
62. Garca-Alloza M, Subramanian M, Thyssen D, et al. Existing plaques and neuritic abnormalities in APP:PS1 mice are not affected by administration of the gamma-secretase inhibitor LY-411575. Mol Neurodegener 2009;4:19